STOCK TITAN

Zai Lab Limited American Depositary Shares - ZLAB STOCK NEWS

Welcome to our dedicated page for Zai Lab American Depositary Shares news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab American Depositary Shares stock.

Zai Lab Limited (NASDAQ: ZLAB) is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines. Established in 2013 by industry veterans, Zai Lab addresses some of the world's most pressing unmet medical needs with a vision to transform patients’ lives globally.

The company employs a dual approach of in-licensing products and internal research and development to maintain a robust pipeline. This strategy has led to the development of promising drug candidates aimed at treating a range of severe health conditions, particularly in oncology, autoimmune, and infectious diseases.

Core Products and Pipeline:

  • ZL-2306: An investigational treatment for multiple solid tumor types, including ovarian, breast, and lung cancers.
  • ZL-2401: A novel antibiotic belonging to a new class of tetracycline derivatives, significant in the battle against resistant bacterial infections.
  • ZL-2301: An oral small molecule targeting hepatocellular carcinoma (HCC), promising for liver cancer treatment.

Zai Lab's leadership team is acclaimed for their innovative regulatory approval pathways in China, which have expedited the introduction of new therapies. The company's partnerships with global pharmaceutical giants underscore its commitment to conducting world-class clinical development both in China and internationally.

Financially, Zai Lab has strong support from a cadre of leading healthcare investors, ensuring robust backing for its ambitious projects. This financial stability allows the company to explore cutting-edge research and expand its therapeutic offerings continually.

Recent Achievements and Current Projects:

  • Successful initiation of multiple late-stage clinical trials across various therapeutic areas.
  • Establishment of strategic partnerships with multinational pharmaceutical companies to enhance drug development and commercialization.
  • Ongoing expansion of their research facilities to accommodate new projects and collaborations.

Zai Lab remains committed to leveraging its expertise, innovation, and strategic partnerships to bring life-changing therapies to market, ultimately improving patient outcomes worldwide.

Rhea-AI Summary
Zai Lab 's partner Novocure announces positive results from the phase 3 METIS clinical trial showing a significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
-
Rhea-AI Summary
Zai Lab Limited announces the presentation of preclinical data on ZL-1310, an innovative ADC targeting DLL3 for small cell lung cancer and other solid tumors at the European Lung Cancer Congress 2024. ZL-1310 shows high affinity for DLL3 and promising therapeutic potential, leading to a Phase 1 clinical trial initiation in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Summary
Zai Lab Limited to present final overall survival data from the Phase 3 NORA study on ZEJULA at 2024 ESGO and SGO conferences, showcasing the benefit of niraparib maintenance therapy for Chinese patients with platinum-sensitive recurrent ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences clinical trial
Rhea-AI Summary
Zai Lab Limited (ZLAB) senior management team to participate in Leerink Partners Global Biopharma Conference 2024 in Miami Beach on March 11, 2024, with a live webcast available on the company's Investor Relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited (ZLAB) reports total product revenue of $266.7 million for Full-Year 2023, showing 25% y-o-y growth. VYVGART® launch in China and inclusion on NRDL drive success. Three new potential launches expected in 2024. Financially strong with $807.6 million cash position. Strategic priorities focus on growth, profitability, and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
-
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will report financial results for the year ended December 31, 2023, and recent corporate updates on February 28, 2024. The live conference call and webcast will be held at 8:00 a.m. ET (9:00 p.m. HKT) on the same day. Listeners can access the webcast through the company's website and must register in advance. Dial-in details will be provided upon registration. A replay will be available on the website after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
Rhea-AI Summary
Zai Lab Limited (ZLAB) announced Phase 1/2 TRIDENT-1 study data published in The New England Journal of Medicine demonstrate the potential of repotrectinib (TPX-0005) to overcome limitations of first-generation TKIs in terms of durability of responses and activity in ROS1 resistance mutations. The study showed robust intracranial activity in patients with ROS1-positive non-small cell lung cancer, with repotrectinib demonstrating high response rates and durable activity, including in patients with TKI-naïve and TKI-pretreated tumors, ROS1 G2032R resistance mutations, and brain metastases. The findings suggest repotrectinib as a next-generation treatment for ROS1+ NSCLC. The Center for Drug Evaluation of the National Medical Products Administration accepted the New Drug Application for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC after granting priority review in May 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will participate in the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, with a live webcast available on the Investor Relations page of Zai Lab’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary
Zai Lab Limited (ZLAB) announces the inclusion of VYVGART, NUZYRA, and ZEJULA in China's 2023 National Reimbursement Drug List (NRDL), providing patient access to important medications at reduced prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.85%
Tags
none
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced a 22% y-o-y growth in product revenue for Q3 2023, reaching $69.2 million, with VYVGART sales of $4.9 million in China. The company's cash position stands at $822.2 million, and the stock market announcement highlights the successful launch of VYVGART and ZEJULA's leading position in hospital sales for ovarian cancer in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags

FAQ

What is the current stock price of Zai Lab American Depositary Shares (ZLAB)?

The current stock price of Zai Lab American Depositary Shares (ZLAB) is $25.7 as of November 21, 2024.

What is the market cap of Zai Lab American Depositary Shares (ZLAB)?

The market cap of Zai Lab American Depositary Shares (ZLAB) is approximately 2.7B.

What does Zai Lab Limited specialize in?

Zai Lab Limited focuses on the discovery, development, and commercialization of innovative medicines, particularly in oncology, autoimmune, and infectious diseases.

When was Zai Lab Limited founded?

Zai Lab Limited was founded in 2013 by a team of industry veterans.

What are some key products in Zai Lab's pipeline?

Key products include ZL-2306 for various solid tumors, ZL-2401, a novel antibiotic, and ZL-2301, an oral small molecule targeting hepatocellular carcinoma.

How does Zai Lab Limited approach drug development?

Zai Lab employs a dual approach of in-licensing products and internal R&D to develop a rich pipeline of promising drug candidates.

What recent achievements has Zai Lab Limited made?

Recent achievements include initiating multiple late-stage clinical trials, forming strategic partnerships, and expanding research facilities.

Who are the founders of Zai Lab Limited?

The company was founded by industry veterans known for their contributions to China's biotech industry and their successful regulatory filings.

What partnerships has Zai Lab Limited established?

Zai Lab has developed various partnership models with multinational pharmaceutical companies to enhance drug development and commercialization.

Where does Zai Lab Limited conduct clinical development?

Zai Lab conducts clinical development both in China and internationally.

Who backs Zai Lab Limited financially?

A leading group of healthcare investors provides strong financial backing to Zai Lab Limited.

What is Zai Lab Limited's vision?

Zai Lab aims to address the largest unmet medical needs and transform patients’ lives around the world.

Zai Lab Limited American Depositary Shares

Nasdaq:ZLAB

ZLAB Rankings

ZLAB Stock Data

2.75B
97.47M
1.99%
44.88%
4.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SHANGHAI